The approval of Novo Nordisk’s diabetes drug Victoza has led to an unintended benefit for a competitor.
Browsing: Uncategorized
Biomoda’s CyPath diagnostic assay is based on molecular marker technology originally developed at the Los Alamos National Laboratory.
Genomic Health, a developer of genomics-based diagnostic tests, announced on Thursday the worldwide availability of its Oncotype DX Colon Cancer Test.
Below are some updates and developments from the past week.
NuVue Therapeutics is commercializing a site-specific regimen of cancer therapy for soft tissue tumors.
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
Keryx Biopharmaceuticals, Inc. is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.
Two biopharmaceutical companies took a step forward this week with their pipelines for advanced breast cancer.